Bellecapital International Ltd. Acquires 8,728 Shares of AbbVie Inc. $ABBV

Key Points

• Bellecapital International increased its AbbVie stake by 13% in the second quarter, acquiring 8,728 shares for a total holding of 75,615 shares valued at approximately $19.0 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• Analyst sentiment remains positive: Wolfe Research upgraded AbbVie to “outperform,” while several firms raised their price targets. The stock has a consensus “Moderate Buy” rating and an average target price of $275.50.
• AbbVie exceeded quarterly expectations, reporting $3.65 in EPS and $16.99 billion in revenue, up 10.2% year over year. The company also pays a quarterly dividend of $1.73, equivalent to a 2.8% annual yield, though risks include its elevated valuation and pipeline uncertainty.

Bellecapital International Ltd. grew its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 13.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,615 shares of the company's stock after buying an additional 8,728 shares during the quarter. AbbVie makes up 3.0% of Bellecapital International Ltd.'s portfolio, making the stock its 10th largest position. Bellecapital International Ltd.'s holdings in AbbVie were worth $19,028,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Fourpath Capital Management LLC boosted its stake in shares of AbbVie by 31.7% during the 2nd quarter. Fourpath Capital Management LLC now owns 7,115 shares of the company's stock worth $1,791,000 after buying an additional 1,714 shares during the last quarter. Spartan Planning & Wealth Management increased its position in shares of AbbVie by 9.5% in the second quarter. Spartan Planning & Wealth Management now owns 2,630 shares of the company's stock valued at $662,000 after acquiring an additional 229 shares during the last quarter. Pines Wealth Management LLC raised its holdings in AbbVie by 2.6% during the second quarter. Pines Wealth Management LLC now owns 7,808 shares of the company's stock worth $1,965,000 after acquiring an additional 201 shares in the last quarter. Synergy Asset Management LLC raised its holdings in AbbVie by 703.9% during the second quarter. Synergy Asset Management LLC now owns 180,179 shares of the company's stock worth $45,340,000 after acquiring an additional 157,767 shares in the last quarter. Finally, RWQ Financial Management Services Inc. boosted its position in AbbVie by 135.9% during the second quarter. RWQ Financial Management Services Inc. now owns 54,700 shares of the company's stock valued at $13,765,000 after purchasing an additional 31,510 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of analyst reports. Wolfe Research upgraded AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 price target for the company in a research note on Thursday. UBS Group upped their price objective on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research note on Monday, July 13th. Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. BMO Capital Markets raised their target price on shares of AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Finally, Bank of America boosted their target price on shares of AbbVie from $234.00 to $276.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $275.50.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Stock Performance

AbbVie stock opened at $249.20 on Monday. The stock has a 50-day simple moving average of $244.94 and a 200 day simple moving average of $226.16. The stock has a market capitalization of $440.29 billion, a P/E ratio of 70.40, a PEG ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the company earned $2.97 earnings per share. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Wednesday, July 15th. AbbVie's dividend payout ratio is 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source